Treatment of extensively drug-resistant Gram-negative infections in critically ill patients: Outcome of a consensus meeting at the 13th Asia-Pacific Congress of Clinical Microbiology and Infection, October 2012

Journal of Global Antimicrobial Resistance

Volumn 1, Issue 3, 2013, Pages 117-122

  Tambyah, Paul Anantharajah ^a   Hara, Gabriel Levy ^b   Daikos, George L ^c   Falagas, Matthew E ^d,e   Mazzei, Teresita ^f   Mouton, Johan W ^g   Novelli, Andrea ^f   Chen, Baiyi ^h   Wang, Minggui ⁱ   Ko, Wen Chien ^j   Li, Taisheng ^k   Fan, Xinjian ^l   Theuretzbacher, Ursula ^m  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b HOSPITAL DURAND   (Argentina)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF FLORENCE   (Italy)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h CHINA MEDICAL UNIVERSITY   (China)

ⁱ FUDAN UNIVERSITY   (China)

^j NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^k PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^l SICHUAN UNIVERSITY   (China)

^m Center For Anti Infective Agents Vienna   (Austria)

more..

Author keywords

Aminoglycoside; Carbapenems; Colistin; Extensively drug resistant; Gram negative bacteria; Resistance; Tigecycline

Indexed keywords

AMINOGLYCOSIDE; CARBAPENEM DERIVATIVE; COLISTIN; FOSFOMYCIN; MEROPENEM; TIGECYCLINE;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERICIDAL ACTIVITY; CONSENSUS; CRITICALLY ILL PATIENT; DRUG EFFICACY; DRUG INDICATION; DRUG MONITORING; EXTENSIVELY DRUG RESISTANT GRAM NEGATIVE INFECTION; GRAM NEGATIVE INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ROOM TEMPERATURE;

EID: 84882343846     PISSN: 22137165     EISSN: 22137173     Source Type: Journal    
DOI: 10.1016/j.jgar.2013.04.002     Document Type: Review

References (58)

1. U. Theuretzbacher Global antibacterial resistance: the never-ending story Journal of Global Antimicrobial Resistance 2013 10.1016/j.jgar.2013.03.010 in press
2. A.P. Magiorakos, A. Srinivasan, R.B. Carey, Y. Carmeli, M.E. Falagas, and C.G. Giske Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance Clinical Microbiology and Infection 18 2012 268 281
3. L. Poirel, R.A. Bonnin, and P. Nordmann Analysis of the resistome of a multidrug-resistant NDM-1-producing Escherichia coli strain by high-throughput genome sequencing Antimicrobial Agents and Chemotherapy 55 2011 4224 4229
4. M. Hombach, G.V. Bloemberg, and E.C. Böttger Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli Journal of Antimicrobial Chemotherapy 67 2012 622 632
5. G. Kahlmeter, D.F. Brown, F.W. Goldstein, A.P. MacGowan, J.W. Mouton, and A. Osterlund European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria Journal of Antimicrobial Chemotherapy 52 2003 145 148
6. J.W. Mouton, D.F. Brown, P. Apfalter, R. Cantón, C.G. Giske, and M. Ivanova The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach Clinical Microbiology and Infection 18 2012 E37 E45
7. J.S. Esterly, J. Wagner, M.M. McLaughlin, M.J. Postelnick, C. Qi, and M.H. Scheetz Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification Antimicrobial Agents and Chemotherapy 56 2012 4885 4890
8. G.L. Daikos, and A. Markogiannakis Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clinical Microbiology and Infection 17 2011 1135 1141
9. J.L. Kuti, P.K. Dandekar, C.H. Nightingale, and D.P. Nicolau Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem Journal of Clinical Pharmacology 43 2003 1116 1123
10. Y. Hayashi, J. Lipman, A.A. Udy, M. Ng, B. McWhinney, and J. Ungerer β-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia International Journal of Antimicrobial Agents 41 2013 162 166
11. R.A. Keel, C.A. Sutherland, J.L. Crandon, and D.P. Nicolau Stability of doripenem, imipenem and meropenem at elevated room temperatures International Journal of Antimicrobial Agents 37 2011 184 185
12. J.W. Mouton, and A.A. Vinks Continuous infusion of β-lactams Current Opinion in Critical Care 13 2007 598 606
13. E. Durante-Mangoni, A. Grammatikos, R. Utili, and M.E. Falagas Do we still need the aminoglycosides? International Journal of Antimicrobial Agents 33 2009 201 205
14. S. Maraki, M.N. Mavros, D.P. Kofteridis, G. Samonis, and M.E. Falagas Epidemiology and antimicrobial sensitivities of 536 multi-drug-resistant Gram-negative bacilli isolated from patients treated on surgical wards Surgical Infections (Larchmt) 13 2012 326 331
15. M.J. Satlin, C.J. Kubin, J.S. Blumenthal, A.B. Cohen, E.Y. Furuya, and S.J. Wilson Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine Antimicrobial Agents and Chemotherapy 55 2011 5893 5899
16. G.L. Drusano, and A. Louie Optimization of aminoglycoside therapy Antimicrobial Agents and Chemotherapy 55 2011 2528 2533
17. N.A. van Lent-Evers, R.A. Mathôt, W.P. Geus, B.A. van Hout, and A.A. Vinks Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis Therapeutic Drug Monitoring 21 1999 63 73
18. P.J. Bergen, C.B. Landersdorfer, H.J. Lee, J. Li, and R.L. Nation 'Old' antibiotics for emerging multidrug-resistant bacteria Current Opinion in Infectious Diseases 25 2012 626 633
19. L.S. Tzouvelekis, A. Markogiannakis, M. Psichogiou, P.T. Tassios, and G.L. Daikos Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions Clinical Microbiology Reviews 25 2012 682 707
20. M. Paul, J. Bishara, A. Levcovich, M. Chowers, E. Goldberg, and P. Singer Effectiveness and safety of colistin: prospective comparative cohort study Journal of Antimicrobial Chemotherapy 65 2010 1019 1027
21. W. Couet, N. Grégoire, S. Marchand, and O. Mimoz Colistin pharmacokinetics: the fog is lifting Clinical Microbiology and Infection 18 2012 30 39
22. Z.Z. Deris, H.H. Yu, K. Davis, R.L. Soon, J. Jacob, and C.K. Ku The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model Antimicrobial Agents and Chemotherapy 56 2012 5103 5112
23. A. Michalopoulos, and E. Papadakis Inhaled anti-infective agents: emphasis on colistin Infection 38 2010 81 88
24. D.P. Kofteridis, C. Alexopoulou, A. Valachis, S. Maraki, D. Dimopoulou, and D. Georgopoulos Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched-control study Clinical Infectious Diseases 51 2010 1238 1244
25. A.L. Kwa, M.E. Falagas, A. Michalopoulos, and V.H. Tam Benefits of aerosolized colistin for ventilator-associated pneumonia: absence of proof versus proof of absence? Clinical Infectious Diseases 52 2011 1278 1279
26. H.M. Arnold, A.M. Sawyer, and M.H. Kollef Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia Respiratory Care 57 2012 1226 1233
27. D.F. Florescu, F. Qiu, M.A. McCartan, C. Mindru, P.D. Fey, and A.C. Kalil What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression Clinical Infectious Diseases 54 2012 670 680
28. T. Khawcharoenporn, A. Apisarnthanarak, and L.M. Mundy Intrathecal colistin for drug-resistant Acinetobacter baumannii central nervous system infection: a case series and systematic review Clinical Microbiology and Infection 16 2010 888 894
29. I. Karaiskos, L. Galani, F. Baziaka, and H. Giamarellou Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literature review International Journal of Antimicrobial Agents 2013 10.1016/j.ijantimicag.2013.02.006 pii:S0924-8579(13) 00054-X
30. D.M. Livermore, M. Warner, S. Mushtaq, M. Doumith, J. Zhang, and N. Woodford What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline International Journal of Antimicrobial Agents 37 2011 415 419
31. O. Zarkotou, S. Pournaras, G. Altouvas, V. Pitiriga, M. Tziraki, and V. Mamali Comparative evaluation of tigecycline susceptibility testing methods for expanded-spectrum cephalosporin- and carbapenem-resistant Gram-negative pathogens Journal of Clinical Microbiology 50 2012 3747 3750
32. T. Spanu, G. De Angelis, M. Cipriani, B. Pedruzzi, T. D'Inzeo, and M.A. Cataldo In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli Antimicrobial Agents and Chemotherapy 56 2012 4516 4518
33. S.M. Bhavnani, C.M. Rubino, J.P. Hammel, A. Forrest, N. Dartois, and C.A. Cooper Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline Antimicrobial Agents and Chemotherapy 56 2012 1065 1072
34. P. Prasad, J. Sun, R.L. Danner, and C. Natanson Excess deaths associated with tigecycline after approval based on noninferiority trials Clinical Infectious Diseases 54 2012 1699 1709
35. US Food and Drug Administration (FDA). FDA drug safety communication: increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. http://www.fda.gov/Drugs/DrugSafety/ ucm224370.htm [accessed March 2013].
36. S.A. Van Wart, J.S. Owen, E.A. Ludwig, A.K. Meagher, J.M. Korth-Bradley, and B.B. Cirincione Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections Antimicrobial Agents and Chemotherapy 50 2006 3701 3707
37. C.M. Rubino, S.M. Bhavnani, A. Forrest, G. Dukart, N. Dartois, and A. Cooper Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia Antimicrobial Agents and Chemotherapy 56 2012 130 136
38. Z.A. Qureshi, D.L. Paterson, B.A. Potoski, M.C. Kilayko, G. Sandovsky, and E. Sordillo Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens Antimicrobial Agents and Chemotherapy 56 2012 2108 2113
39. KPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin Antimicrobial Agents and Chemotherapy 54 2010 526 529
40. O. Asuphon, P. Montakantikul, J. Houngsaitong, P. Sonthisombat, and P. Kiratisin Optimizing fosfomycin dosing for treatment of Pseudomonas aeruginosa infections in critically-ill patients based on pharmacokinetics/pharmacodynamics (PK/PD) target 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 9-12 September 2012; San Francisco, CA, Washington, DC 2012 ASM Press A-1279
41. A. Michalopoulos, S. Virtzili, P. Rafailidis, G. Chalevelakis, M. Damala, and M.E. Falagas Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation Clinical Microbiology and Infection 16 2010 184 186
42. M.E. Falagas, A.C. Kastoris, A.M. Kapaskelis, and D.E. Karageorgopoulos Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review Lancet Infectious Diseases 10 2010 43 50
43. D.E. Karageorgopoulos, V. Miriagou, L.S. Tzouvelekis, K. Spyridopoulou, and G.L. Daikos Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases Journal of Antimicrobial Chemotherapy 67 2012 2777 2779
44. D.E. Karageorgopoulos, R. Wang, X.H. Yu, and M.E. Falagas Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens Journal of Antimicrobial Chemotherapy 67 2012 255 268
45. C.L. Abad, A. Kumar, and N. Safdar Antimicrobial therapy of sepsis and septic shock - when are two drugs better than one? Critical Care Clinics 27 2011 e1 e27
46. M. Paul, and L. Leibovici Combination antimicrobial treatment versus monotherapy: the contribution of meta-analyses Infectious Disease Clinics of North America 23 2009 277 293
47. M. Tumbarello, P. Viale, C. Viscoli, E.M. Trecarichi, F. Tumietto, and A. Marchese Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy Clinical Infectious Diseases 55 2012 943 950
48. M. Akova, G.L. Daikos, L. Tzouvelekis, and Y. Carmeli Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria Clinical Microbiology and Infection 18 2012 439 448
49. N. Safdar, J. Handelsman, and D.G. Maki Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis Lancet Infectious Diseases 4 2004 519 527
50. K.Z. Vardakas, G.S. Tansarli, I.A. Bliziotis, and M.E. Falagas β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis International Journal of Antimicrobial Agents 41 2013 301 310
51. M. Paul, I. Benuri-Silbiger, K. Soares-Weiser, and L. Leibovici β lactam monotherapy versus β lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials British Medical Journal 328 2004 668
52. A. Kumar, R. Zarychanski, B. Light, J. Parrillo, D. Maki, and D. Simon Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis Critical Care Medicine 38 2010 1773 1785
53. V.H. Tam, K.T. Chang, K. Abdelraouf, C.G. Brioso, M. Ameka, and L.A. McCaskey Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa Antimicrobial Agents and Chemotherapy 54 2010 1160 1164
54. L.L. Maragakis, and T.M. Perl Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options Clinical Infectious Diseases 46 2008 1254 1263
55. C.M. Drapeau, E. Grilli, and N. Petrosillo Rifampicin combined regimens for Gram-negative infections: data from the literature International Journal of Antimicrobial Agents 35 2010 39 44
56. G.G. Zhanel, C.D. Lawson, S. Zelenitsky, B. Findlay, F. Schweizer, and H. Adam Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin Expert Review of Anti-infective Therapy 10 2012 459 473
57. U. Theuretzbacher Accelerating resistance, inadequate antibacterial drug pipelines and international responses International Journal of Antimicrobial Agents 39 2012 295 299
58. J.W. Mouton, P.G. Ambrose, R. Canton, G.L. Drusano, S. Harbarth, and A. MacGowan Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective Drug Resistance Updates 14 2011 107 117